LOGIN  |  REGISTER
C4 Therapeutics
Viking Therapeutics

Valeo Pharma Announces Listing To The Toronto Stock Exchange

March 28, 2022 | Last Trade: C$0.05 0.00 0.00

The Company's shares and warrants to start trading on March 29th, 2022

Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has received final approval for the listing of its common shares and warrants on the Toronto Stock Exchange ("TSX").

Valeo Pharma Logo (CNW Group/Valeo Pharma Inc.)

The Company's common shares and warrants will commence trading on the TSX effective as of market open on Tuesday March 29, 2022 (the "Effective Date"), and will continue to trade under the current symbols of "VPH", "VPH.WT" and "VPH.WT.A. The Company's commons shares and warrants will concurrently be de-listed from the CSE as of the Effective Date.

"Listing on the TSX, Canada's senior stock exchange, is an important step supporting our development as a leading Canadian pharmaceutical company", said Steve Saviuk, CEO. "The TSX platform  enhances Valeo's exposure to a broader investor audience which will benefit all our shareholders".

About Valeo Pharma

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology, Neurodegenerative Diseases, Oncology and other specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.

Forward Looking Statements

This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

Recursion

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB